This article is more than 5 years old. Information may no longer be current.

FDA approves iDESIGN Refractive Studio for LASIK

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Johnson & Johnson Vision’s iDESIGN Refractive Studio LASIK platform has been approved by the FDA, according to a press release.

The iDESIGN, which uses topography-integrated, wavefront-guided technology, allows physicians to take precise measurements of both the inside and outside of the eye to personalize the LASIK procedure to each patient, the release said.

It has been approved for myopia, hyperopia and mixed astigmatism, and is the only LASIK platform for monovision LASIK in presbyopic myopia.

“The new iDESIGN Refractive Studio provides surgeons with the ability to deliver one-of-a-kind custom laser vision correction for each patient to have excellent visual outcomes following their LASIK procedure,” Jonathan Talamo, MD, chief medical officer and worldwide vice president of medical and clinical affairs at Johnson & Johnson Vision, said in the release.

The platform is expected to be commercially available in the third quarter of this year.